Suitability of infrared spectroscopy for drug checking in harm reduction centres.

Drug checking is a service for people who use drugs that includes product analysis and an individual interview including results feedback and harm reduction counselling. It uses different analytical methods but few studies demonstrate their value in current practice. The main objective of this work is to compare the analytical performance of IR spectroscopy to laboratory reference method in the context of drug checking in a harm reduction centre. The secondary objectives are to carry out a description of the people who use drugs requesting a product analysis, and to compare the assumed compositions of products purchased with their real compositions. During 2018, all requests for drug testing analysis were included for on-site analysis by IR spectrometry in a harm reduction center and verified by the reference method (UPLC-HRMS) at Bordeaux University Hospital Center. Socioeconomic and product data were also collected. One hundred and thirty-six samples were collected. The results obtained with IR and UPLC-HRMS were compared. IR spectrometry results did not match with reference method in 8 % (n=11) of cases, corresponding to blotters, cannabis and some psychoactive substances present in mixture or in small quantities. Among the products collected, only 5.1 % (n=7) did not correspond to the declared product, either alone or with adulterants. The IR spectrometer allows a simple and rapid detection of at least one molecule, most often the one of interest. However, it is limited to powder and tablet type matrices and is not suitable for blotters, cannabis, mixed or low content substances for which high resolution mass spectrometry remains the reference method.

[1]  M. Barratt,et al.  The utility of drug checking services as monitoring tools and more: A response to Pirona et al. , 2017, The International journal on drug policy.

[2]  R. Day,et al.  Drug checking to improve monitoring of new psychoactive substances in Australia , 2016, The Medical journal of Australia.

[3]  K. Pueschel,et al.  Mass poisoning with NPS: 2C-E and Bromo-DragonFly , 2018, International Journal of Legal Medicine.

[4]  R. de la Torre,et al.  Acute Pharmacological Effects of 2C-B in Humans: An Observational Study , 2018, Front. Pharmacol..

[5]  M. Ray,et al.  Fatal Toxic Leukoencephalopathy Secondary to Overdose of a New Psychoactive Designer Drug 2C-E (“Europa”) , 2012, Proceedings.

[6]  E. Wood,et al.  Initial results of a drug checking pilot program to detect fentanyl adulteration in a Canadian setting. , 2018, Drug and alcohol dependence.

[7]  M. Barratt,et al.  Results of an international drug testing service for cryptomarket users. , 2016, The International journal on drug policy.

[8]  M. Farré,et al.  Patterns of use and toxicity of new para‐halogenated substituted cathinones: 4‐CMC (clephedrone), 4‐CEC (4‐chloroethcatinone) and 4‐BMC (brephedrone) , 2017, Human psychopharmacology.

[9]  Kara L Lynch,et al.  Role of liquid chromatography–high-resolution mass spectrometry (LC-HR/MS) in clinical toxicology , 2012, Clinical toxicology.

[10]  M. Farré,et al.  Something New about Something Old: A 10-Year Follow-Up on Classical and New Psychoactive Tryptamines and Results of Analysis , 2017, Journal of psychoactive drugs.

[11]  M. Farré,et al.  The hidden web and the fentanyl problem: Detection of ocfentanil as an adulterant in heroin. , 2017, The International journal on drug policy.

[12]  Marcio Talhavini,et al.  Discrimination and quantification of cocaine and adulterants in seized drug samples by infrared spectroscopy and PLSR. , 2015, Forensic science international.

[13]  Jeff Powell,et al.  An overview of forensic drug testing methods and their suitability for harm reduction point-of-care services , 2017, Harm Reduction Journal.

[14]  S. Sherman,et al.  An assessment of the limits of detection, sensitivity and specificity of three devices for public health-based drug checking of fentanyl in street-acquired samples. , 2020, The International journal on drug policy.

[15]  Susan G. Sherman,et al.  Stakeholder perspectives on implementing fentanyl drug checking: Results from a multi-site study. , 2019, Drug and alcohol dependence.

[16]  I like the old stuff better than the new stuff? Subjective experiences of new psychoactive substances. , 2017, The International journal on drug policy.

[17]  Claudio Vidal Giné,et al.  Crystals and tablets in the Spanish ecstasy market 2000-2014: Are they the same or different in terms of purity and adulteration? , 2016 .

[18]  M. Barratt,et al.  Pill testing or drug checking in Australia: Acceptability of service design features , 2018, Drug and alcohol review.

[19]  E. Wood,et al.  Detecting fentanyl using point-of-care drug checking technologies: A validation study. , 2020, Drug and alcohol dependence.

[20]  T. Kerr,et al.  "We don't got that kind of time, man. We're trying to get high!": Exploring potential use of drug checking technologies among structurally vulnerable people who use drugs. , 2019, The International journal on drug policy.